Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 19/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13413634 | 1.00 | CETP (0.52) | CETPNR1I2KCNN4 | |
| SCHEMBL13413237 | 0.84 | CETP (0.50) | CETPNR1I2 | |
| SCHEMBL13413235 | 0.84 | CETP (0.50) | CETPNR1I2 | |
| SCHEMBL15744010 | 0.84 | CETP (0.46) | CETPNR1I2KCNN4 | |
| SCHEMBL15744012 | 0.84 | CETP (0.46) | CETPNR1I2KCNN4 | |
| SCHEMBL13394559 | 0.82 | CETP (0.47) | CETPNR1I2KCNN4 | |
| SCHEMBL13394557 | 0.82 | CETP (0.47) | CETPNR1I2KCNN4 | |
| SCHEMBL22222386 | 0.81 | CETP (0.48) | CETPNR1I2 | |
| SCHEMBL20794178 | 0.81 | CETP (0.48) | CETPNR1I2 | |
| SCHEMBL13547529 | 0.76 | CETP (0.43) | CETPNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885KCNN4 4403/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885KCNN4 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.